US 12,458,672 B2
Use of microbial communities for human and animal health
Sam Possemiers, Zwijnaarde (BE); Massimo Marzorati, Brussels (BE); Tom Van De Wiele, Merelbeke (BE); Ilse Scheirlinck, Gentbrugge (BE); Pieter Van Den Abeele, Lokeren (BE); Selin Bolca, Zwijnaarde (BE); and Davide Gottardi, Ghent (BE)
Assigned to Universiteit Gent, Ghent (BE); and Microbial Resource Management Health NV (MRM Health), Ghent (BE)
Filed by Universiteit Gent, Ghent (BE); and Microbial Resource Management Health NV (MRM Health), Ghent (BE)
Filed on Oct. 15, 2021, as Appl. No. 17/502,454.
Application 17/502,454 is a continuation of application No. 17/386,266, filed on Jul. 27, 2021.
Application 17/386,266 is a continuation of application No. 16/068,470, granted, now 11,096,971, previously published as PCT/EP2017/052422, filed on Feb. 3, 2017.
Claims priority of application No. 16154288 (EP), filed on Feb. 4, 2016.
Prior Publication US 2022/0023357 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/747 (2015.01); A23L 33/135 (2016.01); A61K 9/00 (2006.01); A61K 35/00 (2006.01); A61K 35/74 (2015.01); A61K 35/741 (2015.01); A61K 35/744 (2015.01); A61K 35/745 (2015.01); A61P 1/14 (2006.01); C12N 1/20 (2006.01)
CPC A61K 35/747 (2013.01) [A23L 33/135 (2016.08); A61K 9/0031 (2013.01); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 35/74 (2013.01); A61K 35/741 (2013.01); A61K 35/744 (2013.01); A61K 35/745 (2013.01); A61P 1/14 (2018.01); C12N 1/20 (2013.01); A23V 2002/00 (2013.01); A23V 2400/169 (2023.08); A23V 2400/513 (2023.08); A23V 2400/533 (2023.08); A61K 2035/115 (2013.01); Y02A 50/30 (2018.01)] 27 Claims
 
1. A method for reduction of symptoms associated with a gastro-intestinal condition, comprising:
administering a composition to a subject having a gastro-intestinal condition, wherein the composition comprises:
at least 10 5 colony-forming units in total of bacterial isolates, wherein the bacterial isolates in the composition have been co-cultured in a dynamic simulator of the gastro-intestinal tract in vitro together for at least one day to form a functional microbial network, wherein the functional microbial network produces a higher amount of butyrate when measured by gas chromatography after 48 hours of in vitro growth compared to an amount of butyrate generated by an equivalent amount of bacterial isolates that have not been co-cultured, and wherein the functional microbial network comprises:
at least one lactate or acetate producing bacterial species selected from a species of: Lactobacilli or Enterococci, or at least one fiber degrading bacterial species selected from a species of: Bifidobacteria or Bacteroides, or at least one mucin degrading bacterial species comprising Akkermansia muciniphila; and
at least one butyrate or propionate producing bacterial species selected from: Anaerostipes caccae, Butyricicoccus pullicaecorum, Faecalibacterium prausnitzii, Roseburia hominis, Roseburia inulinivorans, Clostridium butyricum, Bacteroides thetaiotaomicron, Bacteroides vulgatus, and Akkermansia muciniphila.